![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_open_medium.gif)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_restricted_medium.gif)
An Improved Synthesis of Finasteride from 4-Androsten-3,17-Dione
Subscribe/Renew Journal
An improved synthesis of 3-oxo-4-aza-5α-androst-1-ene-17β-(N-tert-butylcarboxamide), commonly known as finasteride (1), a drug widely used for the treatment of benign prostatic hyperplasia (BPH), has been implemented via seven steps in an overall yield of 20.01% starting from 4-androsten-3,17-dione (AD). Conditions of several steps have been improved to be less expensive and more commercially viable compared to reported synthesis in literature.
Keywords
Finasteride, Benign Prostatic Hyperplasia, Androst-4-En-3,17-Dione, Synthesis.
Subscription
Login to verify subscription
User
Font Size
Information
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 209
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 0